Liquid fructose supplementation in LDL-R-/- mice fed a western-type diet enhances lipid burden and atherosclerosis despite identical calorie consumption

IJC Metabolic and Endocrine

Volumn 9, Issue , 2015, Pages 12-21

  Hutter, Natalia ^a   Baena, Miguel ^a   Sangüesa, Gemma ^a   Dávalos, Alberto ^e   Latasa, María Jesús ^e   Escolà Gil, Joan Carles ^c,d   Sánchez, Rosa María ^a,b   Roglans, Núria ^a,b   Alegret, Marta ^a,b   Laguna, Juan Carlos ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e CSIC   (Spain)

Author keywords

CVD; Inflammation; Lipid metabolism; Macrophages; NAFLD; Sugar sweetened beverages

Indexed keywords

CHOLESTEROL; FRUCTOSE; LEPTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MICRORNA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; LIPID STORAGE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN DIET;

EID: 84949192587     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2015.10.002     Document Type: Article

References (44)

1. Ezzati M., Riboli E. Behavioral and dietary risk factors for noncommunicable diseases. N. Engl. J. Med. 2013, 369:954-964.
2. Schmidt L.A. The toxic truth about sugar. Nature 2012, 482:27-29.
3. Maersk M., Belza A., Stødkilde-jørgensen H., Ringgaard S., Chabanova E., Thomsen H., Pedersen S.B., Astrup A., Richelsen B. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study 1-3. Am. J. Clin. Nutr. 2012, 95:283-289.
4. Zhang Y.H., An T., Zhang R.C., Zhou Q., Huang Y., Zhang J. Very high fructose intake increases serum LDL-cholesterol and total cholesterol: a meta-analysis of controlled feeding trials 1-3. J. Nutr. 2013, 143:1391-1398.
5. The InterAct consortium Consumption of sweet beverages and type 2 diabetes incidence in European adults: results from EPIC-InterAct. Diabetologia 2013, 56:1520-1530.
6. Fung T.T., Malik V., Rexrode K.M., Manson J.E., Willett W.C., Hu F.B. Sweetened beverage consumption and risk of coronary heart disease. Am. J. Clin. Nutr. 2009, 89:1037-1042.
7. de Koning L., Malik V.S., Kellogg M.D., Rimm E.B., Willett W.C., Hu F.B. Sweetened beverage consumption, incident coronary heart disease, and biomarkers of risk in men. Circulation 2012, 125:1735-1741.
8. Yang Q., Zhang Z., Gregg E.W., Flanders W.D., Merritt R., Hu F.B. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern. Med. 2014, 174:516-524.
9. Mayes P. Intermediary metabolism of fructose. Am. J. Clin. Nutr. 1993, 58:754S-765S.
10. Vilà L., Rebollo A., Adalsteisson G.S., Alegret M., Merlos M., Roglans N., Laguna J.C. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol. Appl. Pharmacol. 2011, 251:32-40.
11. Roglans N., Vilà L., Farré M., Alegret M., Sánchez R.M., Vázquez-Carrera M., Laguna J.C. Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats. Hepatology 2007, 45:778-788.
12. Rebollo A., Roglans N., Baena M., Sánchez R.M., Merlos M. Liquid fructose downregulates Sirt1 expression and activity and impairs the oxidation of fatty acids in rat and human liver cells. Biochim. Biophys. Acta 1841, 2014:514-524.
13. Vilà L., Roglans N., Perna V., Sánchez R.M., Vázquez-Carrera M., Alegret M., Laguna J.C. Liver AMP/ATP ratio and fructokinase expression are related to gender differences in AMPK activity and glucose intolerance in rats ingesting liquid fructose. J. Nutr. Biochem. 2011, 22:741-751.
14. Rebollo A., Roglans N., Baena M., Padrosa A., Sánchez R.M., Merlos M., Alegret M., Laguna J.C. Liquid fructose down-regulates liver insulin receptor substrate 2 and gluconeogenic enzymes by modifying nutrient sensing factors in rats. J. Nutr. Biochem. 2014, 25:250-258.
15. Tangirala R.K., Rubin E.M., Palinslcil W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res. 1995, 36:2320-2328.
16. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
17. Julve J., Escolà-Gil J.C., Rotllan N., Fiévet C., Vallez E., de la Torre C., Ribas V., Sloan J.H., Blanco-Vaca F. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome. Arterioscler. Thromb. Vasc. Biol. 2010, 30:232-238.
18. Dweep H., Sticht C., Pandey P., Gretz N. miRWalk-database: prediction of possible miRNA binding sites by 'walking' the genes of three genomes. J. Biomed. Inform. 2011, 44:839-847.
19. Hsu S.D., Lin F.M., Wu W.Y., Liang C., Huang W.C., Chan W.L., Tsai W.T., Chen G.Z., Lee C.J., Chiu C.M., Chien C.H., Wu M.C., Huang C.Y., Tsou A.P., Huang H.D. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 2011, 39:163-169.
20. Zhang Y., Ramos K.S. The development of abdominal aortic aneurysms in mice is enhanced by benzo(a)pyrene. Vasc. Health Risk Manag. 2008, 4:1095-1102.
21. Sahini N., Borlak J. Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes. Prog. Lipid Res. 2014, 54:86-112.
22. Fernández-Hernando C., Ramírez C.M., Goedeke L., Suárez Y. MicroRNAs in metabolic disease. Arterioscler. Thromb. Vasc. Biol. 2013, 33:178-185.
23. Malik V.S., Popkin B.M., Bray G.A., Després J.-P., Hu F.B. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation 2010, 121:1356-1364.
24. Johnson R.J., Perez-Pozo S.E., Sautin Y.Y., Manitius J., Sanchez-Losada L.G., Feig D.I., Shafiu M., Segal M., Glassock R.J., Shimada M., Roncal C., Nakagawa T. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes. Endocr. Rev. 2009, 30:96-116.
25. DiNicolantonio J.J., Lucan S.C. The wrong white crystals: not salt but sugar as aetiological in hypertension and cardiometabolic disease. Open Heart 2014, 1:e000167.
26. Moghadasian M.H., Frohlich J.J., Mcmanus B.M. Advances in experimental dyslipidemia and atherosclerosis. Lab. Investig. 2001, 81:1173-1183.
27. Suzuki M., Yamamoto D., Suzuki T., Fujii M., Suzuki N., Fujishiro M., Sakurai T., Yamada K. High fat and high fructose diet induced intracranial atherosclerosis and enhanced vasoconstrictor responses in non-human primate. Life Sci. 2006, 80:200-204.
28. Suzuki M., Yamamoto D., Suzuki T., Fujii M., Suzuki N., Fujishiro M., Sukarai T., Yamada K. Effects of fructose-rich high-fat diet on glucose sensitivity and atherosclerosis in nonhuman primate. Methods Find. Exp. Clin. Pharmacol. 2006, 28:609-617.
29. Akira K., Amano M., Okajima F., Okajima F., Hashimoto T., Oikawa S. Inhibitory effects of amlodipine and fluvastatin on the deposition of advanced glycation end products in aortic wall of cholesterol and fructose-fed rabbits. Biol. Pharm. Bull. 2006, 29:75-81.
30. Getz G.S., Reardon C.A. Diet and murine atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2006, 26:242-249.
31. Cannizzo B., Luján A., Estrella N., Lembo C., Cruzado M., Castro C. Insulin resistance promotes early atherosclerosis via increased proinflammatory proteins and oxidative stress in fructose-fed ApoE-KO mice. Exp. Diabetes Res. 2012, 2012:941304.
32. Merat S., Casanada F., Sutphin M., Palinski W., Reaven P. Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1223-1230.
33. Gautron L., Elmquist J.K. Sixteen years of counting: an uptade on leptin in energy balance. J. Clin. Invest. 2011, 121:2087-2093.
34. Subramanian S., Goodspeed L., Wang S., Kim J., Zeng L., Ioannou G.N., Haigh W.G., Yeh M.M., Kowdley K.V., O'Brien K.D., Pennatur S., Chait A. Dietary cholesterol exarcebates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J. Lipid Res. 2011, 52:1626-1635.
35. Fernández-Hernando C., Suárez Y., Rayner K.J., Moore K.J. MicroRNAs in lipid metabolism. Curr. Opin. Lipidol. 2011, 22:86-92.
36. Cheung O., Puri P., Eicken C., Contos M., Mirshahi F., Maher J., Kellum J., Min H., Luketic V., Sanyal A.J. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008, 48:1810-1820.
37. Lavoie J., Gauthier M. Regulation of fat metabolism in the liver: link to non-alcoholic hepatic steatosis and impact of physical exercise. Cell. Mol. Life Sci. 2006, 1-17.
38. Gavrilova O., Haluzik M., Matsusue K., Cutson J.J., Johnson L., Dietz K.R., Nicol C.J., Vinson C., Gonzalez F.J., Reitman M.L. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 2003, 278:34268-34276.
39. Schupp M., Lazar M.A. Endogenous ligands for nuclear receptors: digging deeper. J. Biol. Chem. 2010, 285:40409-40415.
40. Ebbeling C.B., Feldman H.A., Chomitz V.R., Antonelli T.A., Gortmaker S.L., Osganian S.K., Ludwig D.S. A randomized trial of sugar-sweetened beverages and adolescent body weight. N. Engl. J. Med. 2012, 367(15):1407-1416.
41. Charo I.F., Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat. Rev. Drug Discov. 2011, 10:365-376.
42. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., Witztum J.L. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008, 31:811-822.
43. Shaw D.J., Seese R., Ponnambalam S., Ajjan R. The role of lectin-like oxidised low-density lipoprotein receptor-1 in vascular pathology. Diab. Vasc. Dis. Res. 2014, 11:410-418.
44. Brasier A.R. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc. Res. 2010, 86:211-218.